(HealthDay News) — A significant correlation between coronary artery disease (CAD) and prostate cancer (PCa) has been found among men participating in a prostate drug trial, according to research published online Feb. 7 in Cancer Epidemiology, Biomarkers & Prevention.
Jean-Alfred Thomas II, M.D., from Duke University in Durham, N.C., and colleagues analyzed data from the four-year REDUCE study, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with prostate-specific antigen (PSA) of 2.5 to 10.0 ng/mL and a negative biopsy. The association between CAD and overall PCa risk and disease grade was examined, adjusting for clinicopathological features, in men who underwent at least one on-study biopsy (6,729 men; 82.8 percent).
The researchers found that 547 men (8.6 percent) had a history of CAD, and they were significantly older and had greater body mass indices, PSA values, and prostate volumes. They were also more likely to have hypertension, hypercholesterolemia, and diabetes, and to take aspirin and statins. CAD correlated with an increased risk of PCa diagnosis (odds ratio [OR], 1.35; P = 0.007), and an elevated risk of low-grade (OR, 1.34; P = 0.02) and high-grade disease (OR, 1.34; P = 0.09).
“Ultimately, if the relationship between CAD and PCa risk is confirmed, then measures proven to reduce CAD, may theoretically also reduce PCa risk,” the authors write.
Several authors disclosed financial ties to GlaxoSmithKline, which partially funded the study.